Gilead Sciences, Inc. $GILD Shares Sold by CIBC Asset Management Inc

CIBC Asset Management Inc lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 403,128 shares of the biopharmaceutical company’s stock after selling 5,835 shares during the quarter. CIBC Asset Management Inc’s holdings in Gilead Sciences were worth $44,747,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of GILD. GoalVest Advisory LLC raised its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter worth $27,000. Putney Financial Group LLC raised its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences during the second quarter worth $30,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 3.7%

GILD opened at $135.93 on Friday. The firm has a market capitalization of $168.65 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. The company’s 50 day simple moving average is $123.98 and its two-hundred day simple moving average is $118.68. Gilead Sciences, Inc. has a 1-year low of $92.26 and a 1-year high of $136.30. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.3%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Analysts Set New Price Targets

GILD has been the topic of several analyst reports. UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Thursday, January 15th. Needham & Company LLC boosted their price target on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Wells Fargo & Company upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, Mizuho upped their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider directly owned 103,221 shares in the company, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 141,757 shares of company stock valued at $17,569,112 in the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.